Last reviewed · How we verify
bexarotene with carboplatin and paclitaxel
bexarotene with carboplatin and paclitaxel is a Retinoid X receptor agonist combined with platinum-based chemotherapy and taxane Small molecule drug developed by Eisai Inc.. It is currently in Phase 3 development for Advanced or metastatic non-small cell lung cancer (Phase 3).
This combination uses bexarotene (a retinoid X receptor agonist) to enhance immune response alongside carboplatin and paclitaxel chemotherapy agents that damage cancer cell DNA and disrupt microtubule function.
This combination uses bexarotene (a retinoid X receptor agonist) to enhance immune response alongside carboplatin and paclitaxel chemotherapy agents that damage cancer cell DNA and disrupt microtubule function. Used for Advanced or metastatic non-small cell lung cancer (Phase 3).
At a glance
| Generic name | bexarotene with carboplatin and paclitaxel |
|---|---|
| Sponsor | Eisai Inc. |
| Drug class | Retinoid X receptor agonist combined with platinum-based chemotherapy and taxane |
| Target | RXR (retinoid X receptor); DNA (carboplatin); β-tubulin (paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bexarotene activates retinoid X receptors (RXR) to promote differentiation and apoptosis of malignant cells while potentially enhancing immune surveillance. Carboplatin is a platinum-based alkylating agent that cross-links DNA, while paclitaxel is a taxane that stabilizes microtubules and prevents cell division. The combination leverages both direct cytotoxic chemotherapy and immune-modulating effects.
Approved indications
- Advanced or metastatic non-small cell lung cancer (Phase 3)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy
- Nausea and vomiting
- Fatigue
- Hypertriglyceridemia (bexarotene-related)
Key clinical trials
- A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer (PHASE1, PHASE2)
- Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bexarotene with carboplatin and paclitaxel CI brief — competitive landscape report
- bexarotene with carboplatin and paclitaxel updates RSS · CI watch RSS
- Eisai Inc. portfolio CI
Frequently asked questions about bexarotene with carboplatin and paclitaxel
What is bexarotene with carboplatin and paclitaxel?
How does bexarotene with carboplatin and paclitaxel work?
What is bexarotene with carboplatin and paclitaxel used for?
Who makes bexarotene with carboplatin and paclitaxel?
What drug class is bexarotene with carboplatin and paclitaxel in?
What development phase is bexarotene with carboplatin and paclitaxel in?
What are the side effects of bexarotene with carboplatin and paclitaxel?
What does bexarotene with carboplatin and paclitaxel target?
Related
- Drug class: All Retinoid X receptor agonist combined with platinum-based chemotherapy and taxane drugs
- Target: All drugs targeting RXR (retinoid X receptor); DNA (carboplatin); β-tubulin (paclitaxel)
- Manufacturer: Eisai Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic non-small cell lung cancer (Phase 3)
- Compare: bexarotene with carboplatin and paclitaxel vs similar drugs
- Pricing: bexarotene with carboplatin and paclitaxel cost, discount & access